Clinical Trials – June 2016

The CFF provided information on the following clinical trials:

06/14/2016 – TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF

This study will look at the effect of adding oral azithromycin to inhaled tobramycin. During the first part of the study, participants will take either oral azithromycin or a placebo in addition to their inhaled tobramycin. After completing the first part of the study, participants have the option to continue in an 8-week study extension. All participants in the extension will take oral azithromycin.

Researchers will test the effect of adding oral azithromycin to inhaled tobramycin by measuring changes in lung function.

This study is for people with CF who are chronically infected with P. aeruginosa and are taking inhaled tobramycin. All participants will continue to use their inhaled tobramycin cycled on/off every 4 weeks throughout the entire study. This study will require lung function tests.

06/28/2016 – Standardized Treatment of Pulmonary Exacerbations II (STOP2)

Pulmonary exacerbations are treated with varying antibiotics for varying time periods based on individual needs determined by patients, their families and care providers. This study will look at the safety and effectiveness of three different lengths of IV antibiotic treatment for pulmonary exacerbations. Participants who respond early to IV treatment will receive antibiotics for 10 or 14 days. Those who do not respond early will receive antibiotics for 14 or 21 days.

Researchers will study the effectiveness of different IV treatment lengths by measuring changes in lung function.

This study is for people with CF who experience a pulmonary exacerbation and are planning to receive IV antibiotic treatment. This study may require lung function tests and/or other measurements.